AstraZeneca to build $1.5B ADC manufacturing plant in Singapore (NASDAQ:AZN) - Seeking Alpha

Roland Magnusson/iStock Editorial via Getty Images

AstraZeneca (NASDAQ:AZN) said it plans to build a $1.5B facility in Singapore to manufacture antibody drug conjugates, or ADCs.

The facility will be the company’s first end-to-end manufacturing plant for ADCs. The plant is expected to come online in 2029.

The project is being supported by the Singapore Economic Development Board. AstraZeneca did not disclose what incentives the Singapore government may have provided for construction of the plant, which was described by the EDB as a “greenfield investment.” The plant will also incorporate green solutions and be designed to emit zero carbon.

AstraZeneca CEO Pascal Soriot said in a statement that Singapore was “one of the world’s most attractive countries for investment, given its reputation for excellence in complex manufacturing.”

More on AstraZeneca

Adblock test (Why?)

Read Again https://news.google.com/rss/articles/CBMifWh0dHBzOi8vc2Vla2luZ2FscGhhLmNvbS9uZXdzLzQxMDgzNzctYXN0cmF6ZW5lY2EtdG8tYnVpbGQtYWRjLW1hbnVmYWN0dXJpbmctcGxhbnQtaW4tc2luZ2Fwb3JlP3NvdXJjZT1mZWVkX3NlY3Rvcl9oZWFsdGhjYXJl0gEA?oc=5

Bagikan Berita Ini